Intensive cholesterol-lowering for high-risk stroke patients
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests a new cholesterol-lowering drug (Tafolecimab) in people who recently had a stroke or mini-stroke caused by plaque buildup in the arteries. The goal is to see if aggressive treatment can reduce the risk of another event.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 35 and 80 years old.
- Your LDL cholesterol must be at least 1.8 mmol/L if you're already on treatment, or at least 2.6 mmol/L if not.
- Your Lp(a) level must be 50 mg/dL or higher.
- Your stroke or mini-stroke must have started 3 to 7 days ago.
- You must have a confirmed blockage of at least 50% or multiple recent strokes on imaging.
- You cannot have had clot-dissolving treatment or a procedure to remove the clot for this event.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a smart computer tool that helps doctors manage your cholesterol treatment with Evolocumab (Repatha). If you have had a recent stroke or mini-stroke and are already taking this medicine, the tool may help you reach your LDL (bad cholesterol) goal faster.
This trial tests adding the anti-clotting drug tirofiban to standard clot removal for people who have a stroke due to a narrowed artery in the brain. The goal is to see if this combination improves outcomes without raising bleeding risk.
This trial tests whether a PCSK9 inhibitor (a drug that lowers cholesterol) can help people who recently had a stroke caused by narrowing of an artery inside the skull. It aims to see if the drug can prevent more strokes and improve recovery.
This study tests whether starting the cholesterol-lowering drug tafolecimab (a PCSK9 inhibitor) early after a heart procedure (PCI) can help people with acute coronary syndrome. It may help lower LDL cholesterol and reduce future heart risks.
This trial tests a new injectable drug called tafolecimab to see if different dosing intervals work well for people with high cholesterol who are already on a stable statin dose. If your cholesterol (LDL-C) is still not at your goal, adding tafolecimab might help.
This trial tests whether quickly starting an aggressive cholesterol-lowering treatment after a stroke improves recovery. It is for people who are about to have a procedure to remove a large blood clot from their brain.
Hear when a new Ischemic Stroke or High-risk TIA (ABCD² ≥ 4) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.